Teva Pharmaceutical Industries Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Richard Francis
Chief executive officer
US$25.7m
Total compensation
| CEO salary percentage | 6.2% |
| CEO tenure | 2yrs |
| CEO ownership | 0.01% |
| Management average tenure | 2.8yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity
Jan 30There's No Escaping Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Muted Revenues Despite A 27% Share Price Rise
Jan 12
Duvakitug And Teva's Growth: A Game Changer In Pharma
Dec 27Teva: Becoming Increasingly Solid, But No Longer Undervalued
Dec 04Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S
Nov 17Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Oct 23Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21Cheap Teva Stock Should Reward Patient Investors
Sep 09Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | -US$2b |
| Sep 30 2024 | n/a | n/a | -US$959m |
| Jun 30 2024 | n/a | n/a | -US$453m |
| Mar 31 2024 | n/a | n/a | -US$478m |
| Dec 31 2023 | US$26m | US$2m | -US$559m |
Compensation vs Market: Richard's total compensation ($USD25.71M) is above average for companies of similar size in the US market ($USD12.55M).
Compensation vs Earnings: Insufficient data to compare Richard's compensation with company performance.
CEO
Richard Francis (56 yo)
2yrs
Tenure
US$25,706,880
Compensation
Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2yrs | US$25.71m | 0.011% $ 2.3m | |
| Executive VP & CFO | 5.1yrs | US$4.94m | 0.064% $ 13.4m | |
| Executive Vice President of International Markets Commercial | 3.4yrs | US$3.73m | 0.028% $ 5.9m | |
| Executive Vice President of European Commercial | 7.2yrs | US$5.16m | 0% $ 0 | |
| Executive Vice President of Global Operations | less than a year | no data | no data | |
| Senior VP & Chief Accounting Officer | 3.2yrs | no data | 0.00046% $ 96.8k | |
| Senior Vice President of Investor Relations & Competitive Intelligence | no data | no data | no data | |
| Senior Vice President | 2.5yrs | no data | no data | |
| Executive VP & Chief Legal Officer | less than a year | no data | no data | |
| Executive VP & CHRO | less than a year | no data | no data | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Internal Auditor | 10.7yrs | no data | no data |
2.8yrs
Average Tenure
53yo
Average Age
Experienced Management: TEVA's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$25.71m | 0.011% $ 2.3m | |
| Independent Chairman of the Board | 10yrs | US$539.99k | 0.036% $ 7.6m | |
| Independent Director | 16yrs | US$340.00k | 0.18% $ 38.8m | |
| Independent Director | 9.3yrs | US$355.00k | 0.0093% $ 2.0m | |
| Independent Director | 7.5yrs | US$340.00k | 0.0084% $ 1.8m | |
| Independent Director | 9.3yrs | US$330.00k | 0.0091% $ 1.9m | |
| Independent Director | 4.6yrs | US$325.46k | 0.0056% $ 1.2m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 3.3yrs | US$330.00k | 0.0043% $ 910.8k | |
| Independent Director | 7.5yrs | US$327.87k | 0.0084% $ 1.8m | |
| Independent Director | 6.6yrs | US$315.25k | 0.0078% $ 1.6m | |
| Independent Director | 1.3yrs | US$176.66k | 0.0011% $ 237.7k |
7.5yrs
Average Tenure
61.5yo
Average Age
Experienced Board: TEVA's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 22:22 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Teva Pharmaceutical Industries Limited is covered by 58 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Balaji Prasad | Barclays |
| Richard Silver | Barclays |